Skip to main content

Advertisement

Log in

Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis

  • Inflammatory Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study was to investigate the safety and effectiveness of an intravitreally injected dexamethasone-containing implant (Ozurdex®) in the treatment of uveitis in children.

Methods

The study group included ten patients (14 eyes) aged 6.5–15 years (mean age 12 years) with intermediate or posterior uveitis who were treated with the Ozurdex implant at two tertiary medical centers between 2009 and 2014, following an insufficient response to standard uveitis therapy. All were followed for at least 6 months (mean 12.2 ± 4.9 months). Clinical data before and after treatment were collected retrospectively from the medical files. Outcome measures were best corrected visual acuity, vitreous haze, and macular thickness. Ocular complications were documented.

Results

Visual acuity improved in 12 eyes (86 %) and intraocular inflammation decreased in 13 eyes (93 %) from 1 week to 3 months after the first injection. Macular edema decreased in all eyes from 1 month to 3 months after the first injection. Five patients underwent repeated injections because of an increase in macular thickness at 3–6 month follow-up. Complications included cataract progression in one patient after one injection and cataract formation in two patients after two injections, and an elevation in intraocular pressure in two patients who responded well to topical treatment.

Conclusions

Both single and repeated injections of a dexamethasone-containing implant are safe and effective for the treatment of noninfectious intermediate and posterior uveitis in children. The duration of the beneficial effect may be limited. More data are required to establish the safety profile of the implant in the pediatric age group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Taylor SRJ, Tomkins-Netzer O, Joshi L, Morarji J, McLoone E, Lightman S (2012) Dexamethasone implant in pediatric uveitis. Ophthalmology 119:2412–2412, e2

    Article  PubMed  Google Scholar 

  2. Smith JA, Mackensen F, Sen HN, Leigh JF, Watkins AS, Pyatetsky D, Tessler HH, Nussenblatt RB, Rosenbaum JT, Reed GF, Vitale S, Smith JR, Goldstein DA (2009) Epidemiology and course of disease in childhood uveitis. Ophthalmology 116:1544–1551, e1

    Article  PubMed Central  PubMed  Google Scholar 

  3. De Smet MD, Taylor SRJ, Bodaghi B, Miserocchi E, Murray PI, Pleyer U, Zierhut M, Barisani-Asenbauer T, LeHoang P, Lightman S (2011) Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 30:452–470

    Article  PubMed  Google Scholar 

  4. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492–513

    Article  CAS  PubMed  Google Scholar 

  5. McDonough AK, Curtis JR, Saag KG (2008) The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 20:131–137

    Article  PubMed  Google Scholar 

  6. Taylor SRJ, Isa H, Joshi L, Lightman S (2010) New developments in corticosteroid therapy for uveitis. Ophthalmologica 224(Suppl):46–53

    Article  CAS  PubMed  Google Scholar 

  7. Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA (2007) Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol 143:840–846

    Article  PubMed  Google Scholar 

  8. Mehta PJ, Alexander JL, Sen HN (2013) Pediatric uveitis: new and future treatments. Curr Opin Ophthalmol 24:453–462

    Article  PubMed  Google Scholar 

  9. Gregory AC, Kempen JH, Daniel E, Kaçmaz RO, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE (2013) Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology 120:186–192

    Article  PubMed Central  PubMed  Google Scholar 

  10. Lowder C, Belfort R, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 129:545–553

    Article  PubMed  Google Scholar 

  11. Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE (2011) Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 118:1916–1926

    Article  PubMed Central  PubMed  Google Scholar 

  12. Arcinue CA, Cerón OM, Foster CS (2013) A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther 29:501–507

    Article  CAS  PubMed  Google Scholar 

  13. Cordero-Coma M, Garzo I, Calleja S, Galán E, Franco M, Ruíz de Morales JG (2013) Preoperative cataract surgery use of an intravitreal dexamethasone implant (Ozurdex) in a patient with juvenile idiopathic arthritis and chronic anterior uveitis. J AAPOS 17:632–634

    Article  PubMed  Google Scholar 

  14. Bratton ML, He Y-G, Weakley DR (2014) Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis. J AAPOS 18:110–113

    Article  PubMed  Google Scholar 

  15. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509–516

    Article  PubMed  Google Scholar 

  16. Rosenberg KD, Feuer WJ, Davis JL (2004) Ocular complications of pediatric uveitis. Ophthalmology 111:2299–2306

    Article  PubMed  Google Scholar 

  17. Sallam A, Comer RM, Chang JH, Grigg JR, Andrews R, McCluskey PJ, Lightman S (2008) Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol 126:200–205

    Article  PubMed  Google Scholar 

  18. Cao JH, Mulvahill M, Zhang L, Joondeph BC, Dacey MS (2014) Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. Ophthalmology 121:1871–1876

    Article  PubMed  Google Scholar 

  19. Bourgault S, Aroichane M, Wittenberg LA, Lavallée A, Ma PE (2013) Treatment of refractory uveitic macular edema with dexamethasone intravitreal implants in a pediatric patient with bilateral granulomatous idiopathic panuveitis: a case report. J Ophthalmic Inflamm Infect 3:6

    Article  Google Scholar 

  20. Khurana RN, Porco TC (2015) Efficacy and safety of dexamethasone intravitreal implant for persistent uveitic cystoid macular edema. Retina

  21. Habot-Wilner Z, Sorkin N, Goldenberg D, Loewenstein A, Goldstein M (2014) Long-term outcome of an intravitreal dexamethasone implant for the treatment of noninfectious uveitic macular edema. Ophthalmologica 232:77–82

    Article  CAS  PubMed  Google Scholar 

  22. Tomkins-Netzer O, Taylor SRJ, Bar A, Lula A, Yaganti S, Talat L, Lightman S (2014) Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology 121:1649–1654

    Article  PubMed  Google Scholar 

  23. Sugar EA, Jabs DA, Altaweel MM, Lightman S, Acharya N, Vitale AT, Thorne JE (2011) Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography. Am J Ophthalmol 152:1044–1052, e5

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Disclosure statement

All authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ruti Sella.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sella, R., Oray, M., Friling, R. et al. Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis. Graefes Arch Clin Exp Ophthalmol 253, 1777–1782 (2015). https://doi.org/10.1007/s00417-015-3124-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-015-3124-x

Keywords

Navigation